Company Overview

Immunome is a company dedicated to developing first-in-class and best-in-class targeted cancer therapies. The company is headquartered at 18702 North Creek Parkway, Suite 100, Bothell, WA 98011. Leveraging advanced technology, Immunome aims to revolutionize cancer treatment through a diverse portfolio of innovative therapies.

Cancer Therapies by Immunome

Immunome's portfolio includes various advanced therapies for cancer treatment. These encompass immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). By focusing on cutting-edge science, the company aims to provide effective treatments for various cancer types.

Proprietary Technology

Immunome utilizes a proprietary memory B cell hybridoma technology. This technology enables rapid screening and functional characterization of novel antibodies and targets. It is a critical component in the development of the company's diverse portfolio of cancer therapies.

IM-4320 Program

The lead program at Immunome, IM-4320, focuses on targeting IL-38, an immunosuppressive cytokine. This program aims to develop a potential treatment for cancer by modulating the immune environment. IM-4320 is a key asset in the company's strategic efforts to treat cancer effectively.

Radioligand Therapy Targeting Fibroblast Activation Protein (FAP)

Immunome is progressing with a Fibroblast Activation Protein (FAP) targeted radioligand therapy. This therapy has potential applications in over 75% of solid tumors. The development of this therapy highlights the company's focus on innovative cancer treatments with wide-reaching applicability.

Acquisition of AL102 for Desmoid Tumor Treatment

Immunome recently completed the acquisition of AL102 from Ayala. AL102 is a Phase 3 asset aimed at treating Desmoid Tumors. This acquisition is a strategic move to expand Immunome's capabilities and therapeutic offerings in the oncology sector.

report flag Report inaccurate information

Immunome Employees

report flag Report inaccurate information

Companies similar to Immunome

Zymeworks is a biopharmaceutical company focused on developing novel medicines for cancer and other serious diseases, utilizing advanced biotherapeutic technologies and engaging in global clinical trials.

People indexed

Arcus Biosciences develops differentiated molecules and combination therapies for cancer treatment, with a clinical pipeline that includes domvanalimab, etrumadenant, and zimberelimab. The company partners with Gilead Sciences and Taiho Pharmaceutical and conducts global clinical trials in various cancer types.

People indexed